ATN-161 administration decreased the ratio of MEFs associated with phospho-ERK1/2-positive cells in the tumour (Supplementary Figure 6), and the tumour growth of MDA-MB-231 cells and WT MEFs; meanwhile, ATN-161 administration did not further decrease the tumour growth of MDA-MB-231 cells and Mint3 KO MEFs (Figure 5l). This evidence concerns the gene MAPK3 and neoplasm.